# Stem Cell Treatment for Lung Injury Caused by Major Infectious Diseases

> **NCT06416709** · PHASE1,PHASE2 · RECRUITING · sponsor: **Cell Energy Life Sciences Group Co. LTD** · enrollment: 80 (estimated)

## Conditions studied

- Lung Injury

## Interventions

- **DRUG:** mesenchymal stem cells
- **OTHER:** saline

## Key facts

- **NCT ID:** NCT06416709
- **Lead sponsor:** Cell Energy Life Sciences Group Co. LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-10
- **Primary completion:** 2026-05-10
- **Final completion:** 2026-05-10
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06416709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06416709, "Stem Cell Treatment for Lung Injury Caused by Major Infectious Diseases". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06416709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*